Neurocognitive and Psychosocial Outcomes in Survivors of Childhood Leukemia With Down Syndrome
Survivors of acute lymphoblastic leukemia (ALL) are at risk for neurocognitive deficits, reduced educational and psychosocial outcomes, and lower quality of life. Neurocognitive assessment is frequently implemented during therapy and continued into survivorship to monitor functioning and to facilitate intervention. Children with Down Syndrome (DS) are at 10 to 20-fold increased risk for leukemia. Survival rates for leukemia patients with DS are comparable to or lower than patients without DS, however, these patients are at greater risk for treatment-related toxicities. Children with preexisting neurodevelopmental conditions, including DS, are systematically excluded from neurocognitive assessment on clinical trials, contributing to a gap in the investigators understanding of outcomes in these patients with preexisting neurocognitive vulnerability. The investigators propose a novel preliminary investigation of functional outcomes in children with DS and childhood leukemia. This study has implications for future treatment of leukemia patients with DS, and may generalize to leukemia patients with other predispositions or preexisting neurodevelopmental conditions (e.g., genetic disorders, acquired brain injury, autism, and epilepsy).
Primary Objective:
- To describe neurocognitive and psychosocial outcomes in survivors of childhood leukemia with Down Syndrome using a novel assessment approach.
研究概览
详细说明
研究类型
注册 (实际的)
联系人和位置
学习地点
-
-
Tennessee
-
Memphis、Tennessee、美国、38105
- St. Jude Children's Research Hospital
-
-
参与标准
资格标准
适合学习的年龄
- 孩子
- 成人
- 年长者
接受健康志愿者
有资格学习的性别
取样方法
研究人群
描述
Inclusion Criteria:
- Patient is an SJCRH patient with a diagnosis of leukemia.
- Diagnosis of Trisomy 21 DS as documented in the medical record
- Completed all cancer-directed therapy at SJCRH, since 1980, and at least 6 months prior to the study visit
- English as the primary language
Exclusion Criteria:
- Documented history of central nervous system (CNS) injury or disease that occurred after completing cancer-directed therapy
- History of or current substance use or abuse
学习计划
研究是如何设计的?
设计细节
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Neurocognitive Outcome
大体时间:Once at participant enrollment
|
Descriptive statistics will be estimated.
|
Once at participant enrollment
|
Psychosocial Outcome
大体时间:Once at participant enrollment
|
Descriptive statistics will be estimated.
|
Once at participant enrollment
|
合作者和调查者
调查人员
- 首席研究员:Lisa M. Jacola, PhD、St. Jude Children's Research Hospital
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
白血病的临床试验
-
Shenzhen Second People's Hospital招聘中白血病 | 骨髓的 | 慢性的 | BCR-ABL (Breakpoint Cluster Region-abelson Murine Leukemia) | 积极的中国